Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2022-12-30 Director's Dealing
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Director's Dealing 2022
Director's Dealing
2022-12-30 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 16, 2022, by Shuttle Pharmaceuticals Holdings, Inc. The content focuses on the submission of matters to a vote of security holders at the company's annual meeting, including election of directors, ratification of auditors, and approval of executive compensation. This corresponds to an official announcement of voting results from a shareholder meeting. The document does not contain full financial statements or detailed financial performance data, so it is not an Annual Report or Interim Report. It is not a proxy solicitation or presentation but specifically reports the voting outcomes. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4529 characters, which is sufficient to contain detailed voting results rather than just a brief announcement or a report publication notice. Confidence is high due to clear identification of voting results and the nature of the filing (Form 8-K Item 5.07).
2022-12-19 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 registration statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. The text includes details about the registration of 3,000,000 shares of common stock under the Shuttle Pharmaceuticals Holdings, Inc. 2018 Equity Incentive Plan. It contains a prospectus summary, risk factors, use of proceeds, selling shareholders, and other information typical of a registration statement. There is no indication that this is an annual report, earnings release, or any other financial report. Instead, it is a capital markets filing related to securities registration for employee stock plans. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-12-12 English
Investor Presentation 2022
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated December 7, 2022, by Shuttle Pharmaceuticals Holdings, Inc. It announces the publication of an updated investor deck on the company's website and furnishes the investor deck as Exhibit 99.1. The text explicitly states that the information is being furnished and shall not be deemed "filed" for certain regulatory purposes, indicating this is an announcement rather than a full report. The document is relatively short (3997 characters) and primarily serves to notify about the availability of the investor presentation rather than containing detailed financial data or analysis. Therefore, this filing is best classified as an Investor Presentation (IP).
2022-12-07 English
Proxy Solicitation & Information Statement 2022
Proxy Solicitation & Information Statement
2022-11-21 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q3 2022
2022-11-14 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.